Coronavirus: Vaccination

(asked on 7th June 2021) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what representations he has received on (a) the efficacy of the Novavax vaccine following its trial and (b) whether volunteers who received two vaccinations as part of the Novavax trial are eligible to receive other types of approved covid-19 vaccines.


Answered by
Nadhim Zahawi Portrait
Nadhim Zahawi
This question was answered on 9th July 2021

The Medicines and Healthcare products Regulatory Agency (MHRA) has regular meetings with Novavax regarding their submission for the vaccine but this is not yet complete. A review of the quality, safety and efficacy data will be required before the MHRA and Commission on Human Medicines can consider approval of the vaccine.

As trial participants become eligible for the vaccination programme, they should discuss with the trial investigator to decide whether they should receive an approved COVID-19 vaccine. This should be informed by whether they had received a placebo or control vaccine, an active vaccine with known efficacy against COVID-19, an experimental trial vaccine product with no current efficacy data and whether they have received a full proposed or incomplete regimen. There is currently a lack of evidence to inform whether a subsequent dose of a different COVID-19 vaccine after a full regimen of experimental vaccine provides any benefit. Subjects should also be made aware that the risks of receiving the deployed vaccine after the trial vaccine are unknown.

Reticulating Splines